Pathogenesis of diabetic neuropathy - do hyperglycemia and aldose reductase inhibitors affect neuroactive steroid formation in the rat sciatic nerves?

Summary

The activation of the polyol pathway through aldose reductase (AR) might be involved in diabetic neuropathy. A considerable structural similarity exists between AR and 3α-hydroxysteroid dehydrogenase (3α-HSD) (both belonging to aldo-keto reductase superfamily); 3α-HSD forms 5α-reduced-3α-hydroxylated steroids, possibly possessing neurotrophic functions. Aim of these experiments was to test “in vitro” in rat sciatic nerves, whether glucose concentrations in the diabetic range might affect the capacity of 3α-HSD to transform dihydroprogesterone (DHP) into tetrahydroprogesterone (THP), a steroid proved to possess neurotrophic effects. The capability of AR inhibitors, drugs used to avoid diabetic complications, to decrease THP formation was also assessed.

3α-HSD activity was evaluated by the conversion of labelled DHP into THP (in a single case dihydrotestosterone was used as substrate, and the corresponding 3α-hydroxylated metabolite was evaluated). Freshly prepared rat sciatic nerve homogenates were used as source of the enzyme. Whole brain, liver and prostate served as “control” tissues.

The results show that glucose added up to a concentration of 400 mg/dL (well above the euglycemic upper level) does not affect the 3α-HSD activity in the sciatic nerve and in the other tissues considered. Similarly, when the enzyme was challenged by two AR inhibitors, tolrestat and sorbinil, added in a concentration about 10 times higher than their IC₅₀ for AR, no significant changes were observed. Analogous results were achieved when DHT was used in presence of glucose (400 mg/dL) and sorbinil. We conclude that hyperglycemia or the administration of the AR inhibitors do not affect 3α-HSD activity in peripheral nerves and therefore do not reduce the formation of steroid metabolites possibly endowed with neurotrophic action.

Key words:

Aldose reductase inhibitors - Neurosteroids - Neuropathy

References

• 1 Bradford M M. A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding.  Anal Biochem. 1976;  72 248-254
• 2 Celotti F, Melcangi R C, Negri-Cesi P, Poletti A. Testosterone metabolism in brain cells and membranes.  J Steroid Biochem Molec Biol. 1991;  40 675-678
• 3 Chakrabarti S, Sima A A, Nakajima T, Yagihashi S, Green D A. Aldose reductase in the BB rat: isolation, immunological identification and localization in the retina and peripheral nerve.  Diabetologia. 1987;  30 244-251
• 4 Costantino L, Rastelli G, Vescovini K, Cignarella G, Vianello P, Del Corso A, Cappiello M, Mura U, Barlocco D. Synthesis, activity, and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors.  J Med Chem. 1996;  39 4396-4405
• 5 Costantino L, Rastelli G, Vianello P, Cignarella G, Barlocco D. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches.  Med Res Rev. 1999;  19 3-23
• 6 Green D A, Lettimer S A. Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications.  N Engl J Med. 1987;  316 599-606
• 7 Gui T, Tanimoto T, Kokai Y, Niscimura C. Presence of a closely related subgroup in the aldo-ketoreductase family of the mouse.  Eur J Biochem. 1995;  227 448-453
• 8 Jez J M, Schlegel B P, Penning T M. Characterization of the substrate binding site in rat liver 3α-hydroxysteroid/dihydrodiol dehydrogenase: the role of tryptophans in ligand binding and protein fluorescence.  J Biol Chem. 1996;  271 30190-30198
• 9 Koenig H L, Schumacher M, Ferzas B, Do Thi A N, Ressouches A, Guennoun R, Jung-Testas I, Robel P, Akwa Y, Baulieu E E. Progesterone synthesis and myelin formation by Schwann cells.  Science. 1995;  268 1500-1504
• 10 Melcangi R C, Celotti F, Ballabio M, Poletti A, Martini L. Testosterone metabolism in peripheral nerves: presence of the 5-alpha-reductase-3-alpha-hydroxysteroid-dehydrogenase enzymatic system in the sciatic nerve of adult and aged rats.  J Steroid Biochem. 1990;  35 145-148
• 11 Melcangi R C, Magnaghi V, Cavarretta I, Martini L, Piva F. Age-induced decrease of glycoprotein Po and myelin basic protein gene expression in rat sciatic nerve. Repair by steroid derivatives.  Neuroscience. 1998;  85 569-578
• 12 Negri-Cesi P, Motta M. Androgen metabolism in the human prostatic cancer cell line LNCaP.  J Steroid Biochem Molec Biol. 1994;  51 89-96
• 13 Nishimura C, Graham C, Hohman T C, Nagata M, Robison W G, Carper D. Characterization of mRNA and genes for aldose reductase in rat.  Biochem Biophys Res Comm. 1988;  153 1051-1059
• 14 Nishimura C, Lou M F, Kinoshita J H. Depletion of myo-inositol and amino acids in galactosemic neuropathy.  J Neurochem. 1987;  48 290-295
• 15 Penning T. Molecular endocrinology of hydroxysteroid dehydrogenases.  Endocrine Rev. 1997;  18 281-305
• 16 Pfeifer M A, Schumer M P, Gelber D A. Aldose reductase inhibitors: the end of an era or the need for different trial designs?.  Diabetes. 46 ((Suppl 2)) 1997;  S82-S89
• 17 Sestany K, Bellini F, Fung S, Abraham N, Treasurywala A, Humber L, Duquesne N S, Dvornik D. N-[[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-N-methylglycine (Tolrestat), a potent, orally active aldose reductase inhibitor.  J Med Chem. 1984;  27 255-256
• 18 Stevens M J, Feldman E L, Green D A. Diabetic peripheral neuropathy. In: DeFronzo (ed) Current Therapy of Diabetes Mellitus Mosby-Year Book Inc 1998: 160-165
• 19 Tomlinson D R, Moriarty R J, Mayer Y H. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with aldose reductase inhibitor Sorbinil.  Diabetes. 1984;  33 470-476
• 20 Yabe-Nishimura C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications.  Pharmacol Rev. 1998;  50 21-33
• 21 Yagihashi S, Yamagishi S, Wada R, Sugimoto K, Baba M, Wong H G, Fujimoto J, Nishimura C, Kokai Y. Galactosemic neuropathy in transgenic mice for human aldose reductase.  Diabetes. 1996;  45 56-59
• 22 Yamaoka T, Nishimura C, Yamashita K, Itakura M, Yamada T, Fujimoto J, Kokai Y. Acute onset of diabetic pathological changes in transgenic mice with human aldose reductase cDNA.  Diabetologia. 1995;  38 255-261